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ABST RACT

The intestinal microbiota represents an interesting and emergent field of
research, with already known implications in metabolic and immunological
functions. Recently, there is increasing evidence that specific gut microbial
populations are associated with cardiovascular diseases. Numerous
completed and ongoing studies aim to evaluate the potential of intestinal
microbiota assessment to improve the prevention, diagnosis, and therapeutic
arsenal of cardiovascular diseases, considering dysbiosis as a cardiovascular
risk factor. There is strong evidence for a correlation between intestinal flora
imbalance and metabolic changes secondary to bacterial metabolites. In this
minireview, we discuss recent data about the connections between intestinal
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microbiota and cardiovascular disease.

Introduction
Microbial cells are an important part of the human
body, surpassing the number of normal cells [1]. Recent
findings have shown that microbiota is responsible for
multiple metabolic effects, interfering with body functions
and creating the predisposition for specific diseases. Thus,
in 2007, the Human Microbiome Project was launched by
the United States National Institutes of Health to
characterize the microbiota and microbe genomics, its role
in human physiology and diseases’ pathogenesis, opening
the door to developing innovative methods to alter
microbial flora [2]. However, identification of certain
microbial species in some particular diseases does not
necessarily demonstrate an etiological relationship with
individual health state or specific diseases. Furthermore,
the project focused on microbial genomics, protein and
metabolite production, and metabolism shifts, based on
three longitudinal studies that had evaluated the role of gut
microbiota in viral respiratory infections [2].

Studies have demonstrated that changes in gut
microbiota composition over the years can interfere with
aging processes such as muscular atrophy or a decrease of
innate immunity and cognitive impairment, opening the
opportunity to investigate the relationship of microbiota
phenotypes and frailty [3]. The presence of a microbial
population is vital for the human body physiology.
However, it was demonstrated that a scarce exposure of the
human body to bacterial organisms or antibiotic treatments
is implicated in inflammatory dysregulation, linked to
metabolic disorders and even to malignant diseases [4-6].
Thus, the current efforts have focused on research for
modalities to repopulate the microbial flora, which proved
to be efficient in trials, with emerging indications of
probiotic bacteria as therapeutic intervention [4-6].
The normal gut microbiota is mainly formed by
anaerobic organisms, such as Firmicutes and
Bacterioidetes, the dominant families, and also
Fusobacteria,
Proteobacteria,
Actinobacteria,
Verrucomicrobia etc. The symbiotic relationship between
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the host and the gut flora represents an important condition
for human evolution. An optimal environment for bacterial
growth is necessary for nutrient absorption and intestinal
barrier, stimulating also the immune system [4].
Some bacterial organisms, such as Lactobacillus
strains, induce the production of reactive oxygen species
into the intestinal cells, which enter into the redox cascade
signaling pathways modulation, stimulating cytoprotective
genes, with cellular proliferation and differentiation, hence
maintaining the integrity and function of the epithelium
[7].
Intestinal bacteria digest the nutrients that the human
body is unable to, such as partially and non-digestible
polysaccharides (starch and fibers), releasing short fatty
chain acids which are absorbed and involved in signaling
pathways, metabolism regulation, and the release of satiety
hormones (peptide YY, glucagon-like peptide-1) [8]. One
significant metabolite is acetate, which demonstrated in
murine experiments a decrease of total body fat as
compared to a control group [9]. In human subjects, acetate
reduced the circulating levels of free fatty acids by
decreasing the lipolysis mechanism and improving insulin
sensitivity [10]. Butyrate, another bacteria metabolite, has
shown a reduction of insulin resistance and body weight in
obese mice [11].
The bacterial metabolites also demonstrated an
unexpected effect on the immunological response, by
mediating the T-cell differentiation into T-cells that
produce interleukin 17, interferon-gamma or interleukin10 through a direct effect on histone enzyme activity,
changing the conformation of the DNA-histone complex
and gene expression [12]. The short-chain fatty acids
decreased the pro-inflammatory response, measured by
serum cytokines levels (tumor necrosis alpha) after four
weeks of prebiotic and probiotic supplementation [13]. In
experimental studies, butyrate decreased the activity of T
helper 1 cells and interleukin 2 production, thus explaining
the beneficial effects in patients with inflammatory bowel
disease [14]. Mainly, the short-chain fatty acids selectively
promote immunological tolerance, with an increase of
regulating T lymphocytes and decrease of effector T cells
[15], influencing even the immune response to other
bacterial antigens such as lipopolysaccharide [16].
The commensal bacterial populations survive in niches,
producing antimicrobial factors that prevent an invading
pathogen to multiply. They ensure that neither one of the
populations out-compete the other, and preserve the
balance. Besides reactive oxygen species and short-chain
fatty acids that are locally produced, bacteria generate
bacteriocins, which are antimicrobial peptides released
extracellular [17]. The Bifidobacterium strains, for
example, produce bacteriocin against Clostridium difficile
and Escherichia coli, to ensure competition [18].

Discussions
Gut microbiota and atherosclerosis
Atherosclerosis represents a cardiovascular risk factor,
the result of multiple concurring causes. It is responsible
not only for coronary artery disease but also for stroke,
peripheral artery disease, etc. Atherosclerosis is
responsible for the majority of acute coronary syndromes
(over 80% of non-ST-segment elevation myocardial
infarction, according to the European Society of
Cardiology Guidelines) [19].
The microorganisms have been implicated in
atherosclerosis since late 1880. Infection with Chlamydia
pneumoniae, an intracellular bacterium, induces the
transformation of macrophages into foam cells, with
leukocyte recruitment, inflammation, and smooth muscular
fiber proliferation, leading to atherosclerotic changes in the
vascular wall [20]. Porphyromonas gingivalis, a gramnegative, anaerobic Bacteroidetes species, is implicated in
periodontal disease and colonic colonization, but it has also
been isolated from atherosclerotic lesions in animal models
[20]. Intestinal presence of Veillonellaceae species, as part
of Firmicutes phylum, has been associated with elevated
circulating vascular cell adhesion molecule 1 (VCAM-1)
in obese children [21]. Elevated circulating levels of
VCAM-1 are correlated with subclinical atherosclerosis
and are implicated in monocyte recruitment, hence
demonstrating its role in diagnosis and secondary
prevention [22].
In murine experiments with apolipoprotein E-deficient
knock-out mice predisposed to atherosclerosis, the germfree group presented increased atherosclerotic plaques
compared to mice with a conventional microbiota, even
when fed with low-lipid diet. This study strengthened the
previous conclusion that commensal flora has a protective
role in atherosclerosis [23].
Gut microbiota and inflammation
Microbial products represent potential activators of the
host immune system, especially lipopolysaccharides and
peptidoglycans that bind to the toll-like receptors (TLR)
and nucleotide-binding oligomerization domain [24].
However, not all subgroups of TLR are implicated in
atherosclerosis. The absence of some TLRs, such as TLR
2 and TLR 4, decreased the rate of lipid accumulation and
monocyte chemotaxis in animal models [8].
In an experimental murine study, after one month of
high-fat meals, an increase in circulating levels of
lipopolysaccharides was correlated with an increase in
insulin resistance and obesity. The result was similar in
normal fed mice but with induced endotoxemia. Thus,
chronic inflammation produced by bacterial metabolites
represents a cornerstone in the pathophysiology of
cardiovascular diseases and can explain why gut
microbiota may be a cardiovascular risk factor [25].
169
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However, obesity itself is a cause of chronic inflammation,
because of immune cells activated by metabolic stress, thus
switching to pro-inflammatory cells, with an increase in
lymphocytes and macrophages population [26] and
alterations of adipocytes such as hypertrophy, ischemia,
and adipocytokine production [27-29].
Gut microbiota and cardiovascular disease
Bacterial metabolites are implicated in immune
responses, as shown above, but butyrate and betahydroxybutyrate were correlated with atherosclerosis
inhibition, thus cardiovascular protection [20]. However,
other bacterial metabolites, such as trimethylamine (TMA)
and trimethylamine N-oxide (TMAO), have demonstrated
a pro-atherogenic effect, with the strongest evidence of
positive correlation with cardiovascular risk in a trial on
4007 patients during 3 years of follow-up [30,31].
Recently, a cohort study demonstrated that the
consumption of processed and unprocessed red meat is
associated with an increased risk of cardiovascular disease
and all-cause mortality [32]. The mechanism can be
explained by the high levels of L-carnitine,
phosphatidylcholine, and choline found in red meat, that
increase the serum TMAO, hence inducing atherosclerosis
by the accumulation of macrophages, alteration of the
reverse cholesterol transport, and increase of thrombocytes
activity [30,33]. The incriminated bacteria may belong to
the Clostridiaceae and Peptostreptococcaeae families
[30,34]. However, some molecules counteract the effects
of TMA and TMAO production, even in a high-choline
diet, such as dimethyl-butanol found in olive oil, grapeseed oil, and red wine [35].
The imbalance of commensal flora, with a
predominance of the phylum Firmicutes over
Bacteroidetes, was associated with obesity [35]. An
increased count of Lactobacillus strains (belonging to the
phylum Firmicutes) was found in diabetic patients [30,36],
although the reasons are unclear. Consistently, the phylum
Bacteroidetes was present at low levels in diabetic patients
[30].

syndrome and an increase of circulating levels of Creactive protein and interleukin 6 [40-42].
Gut microbiota and arterial hypertension
Consistent with the findings described above, patients
with arterial hypertension have increased phylum
Firmicutes to Bacteroidetes ratio. Also, short-chain fatty
acids have been associated with an increase of
Bacteroidetes population in mice and a decrease in blood
pressure values, due mainly to the direct stimulation of
receptors in renal arteries [43-45].

Conclusions
Gut microbiota and its involvement in cardiovascular
diseases represent an emerging field of research that may
offer attractive therapeutic options to a large category of
patients. The changes in the gut microbiota population are
highly correlated with cardiovascular diseases, obesity,
diabetes mellitus, and even malignant diseases. The
characterization of the microbiota genome and isolation of
their metabolites are important steps forward to create new
methods of prevention, diagnosis, and improvement of the
therapeutic interventions. Lifestyle changes, higher food
quality, avoidance of unnecessary antibiotic treatment, and
use of pre- and probiotics are universal preventive
measures.

Highlights
✓ Recent findings have shown that microbiota is
responsible for multiple metabolic effects, interfering
with body functions and creating the predisposition for
specific diseases.
✓ There is increasing evidence that specific gut
microbial populations are associated
with
cardiovascular diseases.
✓ The characterization of the microbiota genome and
isolation of their metabolites are important steps
forward to create new methods of prevention,
diagnosis, and improvement of therapeutic
interventions.

Gut microbiota and heart failure
Heart failure is the final stage of evolution of the
majority of cardiovascular diseases, such as coronary
artery disease, arterial hypertension, etc. Recent studies
have evaluated microbiota involvement in heart failure and
demonstrated an increase in species like Campylobacter,
Shigella, and Candida [36,37]. Intestinal congestion
encountered in heart failure is responsible for the intestinal
epithelial alteration, with secondary bacterial translocation
and persistent endotoxemia that contribute to chronic
inflammation and disease worsening [38,39]. Bacterial
translocation has been associated with an inflammatory
170
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